Innoviva, Inc. (INVA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 337 | 392 | 331 | 310 | 359 | 425 | 443 | 451 |
| Operating profit | $m | 164 | 163 | ||||||
| Net profit | $m | 224 | 266 | 214 | 180 | 23 | 271 | 357 | 205 |
| EPS reported | $ | 3.30 | 4.10 | ||||||
| Operating cashflow per share | $ | 2.92 | 2.61 | ||||||
| Capex per share | $ | 0.16 | 0.04 | ||||||
| FCF per share | $ | 2.77 | 2.56 | ||||||
| Free cash flow | $m | 186 | 188 | ||||||
| Net debt | $m | -293 | -309 | ||||||
| Book value equity | $m | 1,173 | 1,233 | ||||||
| Book value per share | $ | 13.84 | 16.80 | ||||||
| Number of shares | m | 84.76 | 73.42 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 6.06 | 5.18 | ||||||
| P/B LTM | x | 1.15 | 1.09 | ||||||
| P/S LTM | x | 3.17 | 3.04 | ||||||
| P/FCF LTM | x | 7.23 | 7.15 | ||||||
| EV/EBITDA LTM | x | 2.78 | 1.29 | ||||||
| EV/Sales LTM | x | 2.51 | 2.85 | ||||||
| Earnings Yield LTM | % | +16.50% | +19.31% | ||||||
| FCF Yield | % | +13.84% | +13.98% | ||||||
| Quality | |||||||||
| ROE | % | +23.12% | +30.03% | ||||||
| ROIC | % | +8.57% | +8.36% | ||||||
| Operating margin | % | +38.52% | +36.66% | ||||||
| Gross margin | % | +72.33% | +73.09% | ||||||
| FCF/Sales | % | +43.85% | +42.47% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +816.67% | +1038.9% | ||||||
| Sales Growth YoY | % | +18.52% | +23.62% | ||||||
| Net Income Growth YoY | % | +1059.2% | +1427.2% | ||||||
| FCF Growth | % | -1.06% | -0.05% | ||||||
| Operating Profit Growth | % | -1.87% | -2.57% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.69 | 0.70 | ||||||
| Net Debt/EBITDA | x | -0.73 | -0.37 | ||||||
| EBIT/Net interest | x | 9.81 | 8.92 | ||||||
| Net debt/market cap | % | +19.13% | +16.53% | ||||||
| Net debt/Equity | x | -0.25 | -0.25 | ||||||
| Gross debt/equity | x | 0.23 | 0.22 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free